Precision inflammation drugs? Yale spinout Artizan clinches $11M and Biohaven deal to single out bad bacteria

Amber Tong

As a Yale spinout based in New Haven, Artizan Biosciences was pretty familiar with Biohaven — a successful neuro-focused drug developer and “shining star,” as Artizan …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Precision inflammation drugs? Yale spinout Artizan clinches $11M and Biohaven deal to single out bad bacteria

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

Roche outlines commercial manufacturing strategy for GLP-1/GIP assets

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Breaking down silos with a new quantitative approach to drug development

Pre­ci­sion in­flam­ma­tion drugs? Yale spin­out Ar­ti­zan clinch­es $11M and Bio­haven deal to sin­gle out bad bac­te­ria

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Precision inflammation drugs? Yale spinout Artizan clinches $11M and Biohaven deal to single out bad bacteria